文献速递其他结缔组织病

基于临床和生物学表现的聚类分析识别干燥病不同亚组:来自横断面巴黎-萨克雷队列和前瞻性ASSESS队列的数据

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.
PubMed 文献 · Lancet Rheumatol · 2024-03-01

研究纳入法国两个独立队列(横断面巴黎-萨克雷队列534例,前瞻性ASSESS队列395例)的干燥病患者,用无监督多重对应分析基于26个变量识别聚类,并在ASSESS队列验证。两个队列均识别出三个亚组:B细胞活跃且症状负担低(BALS)、高系统性疾病活动(HSA)、低系统性疾病活动且高症状负担(LSAHS)。ASSESS队列随访中BALS组疾病活动和症状状态恶化,淋巴瘤发生于BALS和HSA组。

要点

  • 基于症状和临床生物学表现可识别干燥病三个预后不同的亚组:BALS、HSA、LSAHS。
  • ASSESS队列随访中BALS组ESSPRI评分<5的患者比例从纳入时49%降至第60个月36%(p<0·0001)。
  • 淋巴瘤发生于BALS组5例(3%)和HSA组6例(4%),巴黎-萨克雷队列有淋巴瘤史者均属BALS和HSA组。

核心结论

  • 基于症状和临床生物学表现识别出干燥病三个预后不同的亚组,可能代表不同的异质性病理生理机制、疾病阶段或两者兼有。
  • 这些发现可能对未来治疗试验中的患者分层有意义。

研究设计与样本

  • 研究纳入法国两个独立队列的干燥病患者:横断面巴黎-萨克雷队列534例(女性502例[94%],男性32例[6%],中位年龄54岁[IQR 43-64]),1999年至2022年招募。
  • 前瞻性ASSESS队列395例(女性370例[94%],男性25例[6%],中位年龄53岁[43-63]),2006年至2009年招募。
  • 先采用无监督多重对应分析基于26个变量(含患者报告症状及临床和生物学表现)在巴黎-萨克雷队列识别聚类,再用ASSESS队列验证。
  • 比较各聚类间疾病活动度(ESSDAI)、患者可接受症状状态(ESSPRI)和随访期间淋巴瘤发生率的变化。
  • 将本研究聚类与Tarn等先前描述的基于症状的亚组进行比较。

主要发现

  • 两个队列的层次聚类分析均揭示三个不同亚组:B细胞活跃且症状负担低(BALS)、高系统性疾病活动(HSA)、低系统性疾病活动且高症状负担(LSAHS)。
  • ASSESS队列随访中BALS组疾病活动和症状状态恶化:ESSPRI评分<5的患者第60个月为186例中67例(36%),纳入时为186例中92例(49%)(p<0·0001)。
  • 淋巴瘤发生于BALS组186例中5例(3%),诊断中位时间70个月(IQR 42-104);HSA组158例中6例(4%),诊断中位时间23个月(IQR 13-83)。
  • 巴黎-萨克雷队列中有淋巴瘤史的患者均属于BALS和HSA聚类。
  • 基于症状和临床生物学表现的无监督聚类分类与先前仅基于症状的分类不相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sjögren's disease is a heterogenous autoimmune disease with a wide range of symptoms-including dryness, fatigue, and pain-in addition to systemic manifestations and an increased risk of lymphoma. We aimed to identify distinct subgroups of the disease, using cluster analysis based on subjective symptoms and clinical and biological manifestations, and to compare the prognoses of patients in these subgroups. METHODS: This study included patients with Sjögren's disease from two independent cohorts in France: the cross-sectional Paris-Saclay cohort and the prospective Assessment of Systemic Signs and Evolution of Sjögren's Syndrome (ASSESS) cohort. We first used an unsupervised multiple correspondence analysis to identify clusters within the Paris-Saclay cohort using 26 variables comprising patient-reported symptoms and clinical and biological manifestations. Next, we validated these clusters using patients from the ASSESS cohort. Changes in disease activity (measured by the European Alliance of Associations for Rheumatology [EULAR] Sjögren's Syndrome Disease Activity Index [ESSDAI]), patient-acceptable symptom state (measured by the EULAR Sjögren's Syndrome Patient Reported Index [ESSPRI]), and lymphoma incidence during follow-up were compared between clusters. Finally, we compared our clusters with the symptom-based subgroups previously described by Tarn and colleagues. FINDINGS: 534 patients from the Paris-Saclay cohort (502 [94%] women, 32 [6%] men, median age 54 years [IQR 43-64]), recruited between 1999 and 2022, and 395 patients from the ASSESS cohort (370 [94%] women, 25 [6%] men, median age 53 years [43-63]), recruited between 2006 and 2009, were included in this study. In both cohorts, hierarchical cluster analysis revealed three distinct subgroups of patients: those with B-cell active disease and low symptom burden (BALS), those with high systemic disease activity (HSA), and those with low systemic disease activity and high symptom burden (LSAHS). During follow-up in the ASSESS cohort, disease activity and symptom states worsened for patients in the BALS cluster (67 [36%] of 186 patients with ESSPRI score <5 at month 60 vs 92 [49%] of 186 at inclusion; p<0·0001). Lymphomas occurred in patients in the BALS cluster (five [3%] of 186 patients; diagnosed a median of 70 months [IQR 42-104] after inclusion) and the HSA cluster (six [4%] of 158 patients; diagnosed 23 months [13-83] after inclusion). All patients from the Paris-Saclay cohort with a history of lymphoma were in the BALS and HSA clusters. This unsupervised clustering classification based on symptoms and clinical and biological manifestations did not correlate with a previous classification based on symptoms only. INTERPRETATION: On the basis of symptoms and clinical and biological manifestations, we identified three distinct subgroups of patients with Sjögren's disease with different prognoses. Our results suggest that these subgroups represent different heterogeneous pathophysiological disease mechanisms, stages of disease, or both. These findings could be of interest when stratifying patients in future therapeutic trials. FUNDING: Fondation pour la Recherche Médicale, French Ministry of Health, French Society of Rheumatology, Innovative Medicines Initiative 2 Joint Undertaking, Medical Research Council UK, and Foundation for Research in Rheumatology.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Nguyen Y, Nocturne G, Henry J, et al. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. 2024. PMID: 38437852. doi:10.1016/S2665-9913(23)00340-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。